Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description...
27
Drug Pricing Investigation Staff Report Committee on Oversight and Reform U.S. House of Representatives October 2020 oversight.house.gov Novartis—Gleevec Selected Investigation Documents
Transcript of Drug Pricing Investigation · Novartis Selected Documents . Document # Citation Short Description...
Drug Pricing Investigation
Staff Report Committee on Oversight and Reform
U.S. House of Representatives October 2020
oversight.house.gov
Novartis—Gleevec
Selected Investigation Documents
Novartis Selected Documents Document # Citation Short Description
Novartis 1 CTRL-0003501, at Page 6 August 2016 Presentation Excerpt
Novartis 2 CTRL-0118195, at Slide 3 October 2014 Presentation Excerpt
Novartis 3 CTRL-0007100 2013 Presentation Excerpt
Novartis 4 CTRL-0096280, at Slide 4 November 2012 Presentation Excerpt
Novartis 5 CTRL-0029114, at Slide 1 June 2013 Presentation Excerpt
Novartis 6 CTRL-0007430 July 2013 Emails
Novartis 7 CTRL-0130193, at Slide 8 October 2016 Presentation Excerpt
Novartis 8 CTRL-0027659, at Slide 29 April 2014 Presentation Excerpt
Novartis 9 CTRL-0084047, at Slide 4 July 2015 Presentation Excerpt
Novartis 10 CTRL-0004074 February 2018 Emails
Novartis 11 CTRL-0025801, at Slide 12 January 2015 Presentation Excerpt
Novartis 12 CTRL-0088408, at Page 1 2014 Draft Messaging Document
Novartis 13 CTRL-0061584, at Page 1
Novartis 14 CTRL-0095459, at Slide 19 July 2013 Presentation Excerpt
Novartis 15 CTRL-0092356, at Slide 1 Presentation Excerpt
Financial Analysis
Novartis Document 1
Novartis Document 1
Novartis Document 1
Novartis Document 1
Novartis Document 2
Novartis Document 2
Novartis Document 2
Novartis Document 2
Novartis Document 3
Novartis Document 3
Novartis Document 4
Novartis Document 4
Novartis Document 4
Novartis Document 4
Novartis Document 5
Novartis Document 5
Novartis Document 6
Novartis Document 6
Novartis Document 6
Novartis Document 6
Novartis Document 7
Novartis Document 7
NPC092020_CTRL0130200
Novartis Document 7
Novartis Document 7
Novartis Document 8
Novartis Document 8
Novartis Document 8
Novartis Document 8
Novartis Document 9
Novartis Document 9
Novartis Document 9
Novartis Document 9
Novartis Document 10
Novartis Document 10
Novartis Document 10
Novartis Document 10
Novartis Document 11
Novartis Document 11
Novartis Document 11
Novartis Document 11
Novartis Document 12
Novartis Document 12
Initiative Name Project Owner Project Timing Divisions IncludedUS15411_Gleevec Packaging
General Medicines:
Continued through 2015 to 2016
US General Medicines US Oncology
Completed by: Reviewed by Finance:
Customer's First Initiative Financial Details - Incremental Revenue
Financial Methodology and Assumptions
Initiative Assumptions
Non-Responsive
Improved packaging can have 2 effects on Gleevec sales.1) Improved packaging can increase adherence.2) Improved packaging can slow generic erosion (impact would occur in 2016).
Financial Calculations2.5 billion x 1% adherence increase x 6 months (2nd half of year) = $12,500,000.
Initiative DescriptionAssessing the impact of the new Gleevec packaging with the blister packs. Key Learnings from the Diovan LOE are leveraged as we prepare for the Gleevec LOE. Key learnings shared on Divoan for the Gleevec packaging to blister pack.
Management Results Calculations
Novartis Document 13
Novartis Document 13
Novartis Document 14
Novartis Document 14
Novartis Document 14
Novartis Document 14
Novartis Document 15
Novartis Document 15
